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Abstract 
Background: Peanuts contain potent food allergens and the prevalence of allergy is reported to increase, especially 
in children. Since peanut sensitization may differ between different geographical regions, we wanted to investigate 
the sensitization pattern to the individual peanut allergens in a Norwegian population.
Methods: Cases reported to the Norwegian Food Allergy Register with sera positive to peanut extract were analyzed 
for specific IgE (sIgE) to the recombinant peanut allergens Ara h 1, Ara h 2, Ara h 3, Ara h 8 and Ara h 9 and to birch 
pollen extract. Serum samples negative to the above allergens were analyzed for sIgE to Ara h 6, and sIgE to Pru p 3 in 
peach were analyzed in sera positive to the cross-reactive allergen Ara h 9.
Results: Highest frequency of sIgE to Ara h 2, often co-sensitized to Ara h 1 and 3, were found in the small children 
up to 6 years of age. From the age of 6 years, sensitization to Ara h 8 was predominant. The sIgE levels to the storage 
proteins Ara h 1, 2 and 3 were strongly correlated, as was the sIgE levels to Ara h 8 and birch pollen extract. A low 
sensitization rate of sIgE to Ara h 9 in young adults was observed, which sIgE levels were very strongly correlated to 
Pru p 3.
Conclusion: The sensitization to peanut allergens in a Norwegian population shows a clear age dependent pattern. 
The results add to the previously published research on the sensitization patterns of peanut sensitized patients in dif-
ferent geographical areas.
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Background
Peanut allergy represents a worldwide problem, it is often 
severe, potentially fatal and often persistent throughout 
life [1, 2]. The estimated prevalence of peanut allergy is 
between 0.5 and 2.0 % and appears to be increasing espe-
cially in children [3–5]. An accurate diagnosis of peanut 
allergy is essential since it may represent a significant 
burden on both quality of life and socio-economy [6]. 
Medically supervised oral food challenges (double-blind 
placebo-controlled food challenge, DBPCFC) are con-
sidered the gold standard for diagnosis but are resource-
intensive and may be associated with risk of severe 
allergic reaction or anaphylaxis. In the last decades, how-
ever, several of the peanut allergens have been character-
ized, and analysis of specific IgE (sIgE) on a molecular 
basis has been evaluated as a diagnostic tool for peanut 
allergy [7–10].
The major peanut allergens Ara h 1, 2 and 3 belong to 
the seed storage proteins of the vicilin, conglutin and 
glycinin families, respectively, and are considered to 
be responsible for the original sensitization to peanut 
in susceptible individuals. The seed storage proteins 
are stable and associated with increased risk of severe 
reactions or anaphylaxis. The storage protein Ara h 6, 
a conglutin, has sequence identities to Ara h 2 and is 
also reported to be associated with clinical reactivity to 
peanut. [11]. The relationship between allergy to pol-
len and vegetables, nuts, peanuts and fruits is caused 
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by cross-reacting epitopes due to homology between 
proteins and often give rise to milder symptoms such as 
the oral allergy syndrome. The peanut protein Ara h 8 is 
homologous to the birch pollen protein Bet v 1, and con-
tributes to a substantial cross-reactivity between peanut 
and birch pollen [12]. Cross-reactivity between profilin 
in grass pollen and peanut may also occur [13]. The pea-
nut allergen Ara h 9 is an enzyme-stable non-specific 
lipid transfer protein (LTP) with cross-reactive epitopes 
to other LTPs such as Pru p 3 in peach and Cor a 8 in 
hazelnut [14]. The protein Ara h 9 is reported to be an 
allergen of importance in the Mediterranean area that 
may cause systemic reactions in addition to oral allergy 
syndrome [15].
Recent studies have shown that peanut allergy in USA, 
Australia and different parts of Europe have different 
clinical and immunological patterns, due to differences 
in pollen exposures and differences in dietary traditions 
[13, 14, 16]. Since Norway is a birch endemic country 
and birch pollen gives rise to cross-reactions to peanut, 
we wanted to investigate the sensitization pattern to 
the individual peanut allergens in cases reported to the 
Norwegian National Reporting System and Register of 
Severe Allergic Reactions to Food (the Norwegian Food 
Allergy Register). The cases are submitted with serum 
samples routinely analyzed for a standard panel of aller-
gen extracts [17]. All patients sensitized to peanut extract 
were analyzed for sIgE to the recombinant peanut aller-
gens, in relation to age, gender, onset of reaction, symp-
toms and number of co-sensitizations to other foods and 
to birch pollen.
Methods
Patients
The Norwegian Food Allergy Register was established 
at the Norwegian Institute of Public Health in 2000 in 
collaboration with the Norwegian Food Safety Author-
ity and the National Veterinary Institute [17]. Cases are 
reported on a voluntary basis by first-line doctors and 
submitted together with a serum sample. The reports 
contain patients’ information such as a short case history 
including gender, age, the suspected or incriminating 
food, and onset of reaction, known allergies, symptoms 
and the medication given. A written consent form is 
signed by all patients. A total of 1250 sera submitted to 
the Food Allery Register, routinely analyzed for sIgE to 
a panel of food allergens including peanut, birch- and 
timothy pollen were screened for sIgE to peanut extract. 
Two hundred and fourteen sera had sIgE antibodies to 
peanut extract above the cut off value 0.35 kU/l and were 
included in the study. The 214 patients were equally dis-
tributed between genders, 101 females and 113 males, 
and comprised ages from <1 to 80 years.
Serological analysis
The patient sera were analyzed for sIgE using Immuno-
Cap® (Phadia AB, Uppsala, Sweden). Due to limited vol-
ume of serum available for some of the patients, specific 
IgE antibodies to the three storage proteins Ara h 1, Ara 
h 2 and Ara h 3 were analyzed in 192 patient sera. IgE 
reactivity to Ara h 8, Ara h 9 and to birch pollen extract 
were analyzed in all 214 sera. Sera with sIgE to Ara h 9 
were analyzed for sIgE to the peach allergen Pru p 3 
known to result in cross-reactions to the lipid transfer 
protein. Sera with sIgE antibody levels >0.35  kU/l were 
considered positive. Since ImmunoCap with Ara h 6 is 
not commercially available, sera negative to all the above 
peanut allergens were analyzed for sIgE to Ara h 6 by 
ImmunoSorbent Allergen bioChip assay, ISAC (Thermo 
Fisher Scientific, Oslo, Norway), reported in standard 
units (ISU). ISU >0.3 were considered positive.
Statistics
Pearson correlation was used to establish the strength 
of the relationship between sIgE antibody levels. Syntax 
of recoded combinations of sera with sIgE to the major 
allergens Ara 1, 2 and 3 made it possible to obtain the fre-
quency of all combinations. Frequency analysis and plots 
of the collected data were made using the statistical pro-
grams IBM SPSS Statistics 22 and SigmaPlot 12.3.
Results
Gender, onset of reaction, symptoms and treatment 
in relation to age groups
Frequency analysis of the ages of the 214 patients sensi-
tized to peanut showed four age groups (Fig. 1). As seen 
from the figure, the frequency of sensitization peaked 
Fig. 1 Age distribution of patients with peanut specific IgE show four 
age groups; 0–5 years, 6–25 years, 26–45 years and 46–80 years of age
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at ages 0–5 years, the second group comprised the ages 
from 6 to 25 years, the third group from 26 to 45 years 
and the lowest frequency of sensitization was seen for 
the ages 46 to 80 years. The gender distribution shifted 
from 76:24 % males:females in the small children’s group 
to 23:77  % males:females in the oldest group (Table  1). 
The onset of reaction reported to occur within 1 h after 
intake of the suspected food was highest in the youngest 
group, 97  %, and decreased by age to 69  % in the old-
est group (Table  1). The organ systems reported to be 
most often affected were symptoms in the skin (urti-
caria, and angioedema, sudden itching of eyes and nose), 
most often in combination with gastrointestinal tract 
(oral pruritus, lip swelling, abdominal pain, diarrhea, 
and vomiting) and/or respiratory symptoms (rhinorrhea, 
wheezing, chest tightness, cough, stridor, dyspnoe, and 
respiratory arrest). Patients reported to have symptoms 
affecting more than one organ system, which is related to 
high risk of severe reactions, were highest in the young-
est age group, 76.7  %, declining with age to 54.5  % in 
the oldest age group (Table 1). The four age groups also 
differed in that severe skin symptoms were more often 
reported and loss of consciousness less reported in the 
youngest children. Cardiac arrest was not reported for 
the youngest and the oldest age groups. The therapeutic 
treatment employed was reported to be antihistamines 
alone (23.5 %), in combination with steroids (24.1 %) or 
most commonly in a combination of both epinephrine 
and steroids (32.1  %). Epinephrine alone and steroids 
alone was used in 14.2 and 6.2 % of the reported cases, 
respectively.
Specific IgE levels to the peanut allergens
Seventy-four (38.5  %) of the 192 patient sera analyzed 
had sIgE to the three seed storage proteins Ara h 1, 2, and 
3 in different combinations and sIgE co-sensitized to all 
three proteins was seen in 36 (48.7 %) patient sera. The 
proteins Ara h 1 and Ara h 2 were co-sensitized in 51 
(68.9 %) of the patients, Ara h 2 and Ara h 3 in 39 (52.7 %) 
patients and Ara h 1 and Ara h 3 were co-sensitized in 
38 (51.4 %) patients. Seventeen patients were mono-sen-
sitized to Ara h2, Ara h1 and Ara h3 in frequencies of 9 
(12.2 %), 6 (8.1 %) and 2 (2.7 %), respectively. The IgE lev-
els to all three recombinant allergens were strongly cor-
related (r = 0.65–0.71, p < 0.01).
One hundred and eight (50.5  %) of the 214 patients 
sensitized to peanut extract had sIgE to the birch pollen 
homologue Ara h 8 and were co-sensitized to the birch 
pollen extract in all but two patients. Their sIgE levels 
were strongly correlated (r = 0.61, p < 0.01). Thirty-seven 
(34 %) of the patients with sIgE to Ara h 8 were co-sen-
sitized to the three peanut storage proteins in different 
combinations and showed no correlation with respect to 
sIgE levels.
Twenty-four (11  %) of the 214 patients, showed to be 
sensitized to the lipid transfer protein Ara h 9 with co-
sensitization to Pru p 3 with similar sIgE levels. The sIgE 
levels to the two allergens were very strongly correlated 
(r =  0.99, p  <  0.01). Thirteen (54.2  %) of these patients 
showed co-sensitization in different combinations to Ara 
h 1, 2, 3 and 8.
Thirty-five (16.3 %) patient sera had no sIgE to any of 
the above peanut allergens and were analyzed for sIgE to 
the Ara h 2 homologue Ara h 6. Four (11.4  %) patients 
had sIgE to Ara h 6 with ISU values characterized as low 
(0.3 ISU), moderate to high (4.0 ISU and 7.9 ISU) and 
very high (20.0 ISU).
Thirty-one patient sera were negative to all six peanut 
allergens and had low levels of sIgE to peanut extract. 
These sera were all from patients between the ages 
0–10  years and showed to have sIgE to birch- and/or 
timothy pollen and/or to seeds and nuts indicating cross-
reaction to peanut due to primary sensitization to pollen 
or to seeds or nuts. Sensitization to peanut due to cross-
reactivity between 2S albumins in nuts like walnut, and 
sesame seeds has been reported [18].
Table 1 Gender ratio, onset of reaction within 1 h and symptoms affected in more than one organ system reported in the 
214 patients in relation to the four age groups
The patients sera analyzed for sIgE to Ara h 2 with levels >2.0 kU/l, sIgE to the birch pollen homologue Ara h 8 and birch pollen extract is also shown
a Number of patient sera
b Sera with sIgE to Ara h 2/6 >2.0 kU/l (marker for clinical allergy)
Age group Reported date ImmunoCap® analysis
Years Gender ratio  % Onset of reaction  % Symptoms  % Ara h 2 % Ara h 8 % Birch pollen  %
Male:female <1 h >1 organ affected sIgE >2.0 kU/lb sIgE kU/l sIgE kU/l
0–5 (Na = 43) 76: 24 97 76.7 51.2 23.3 41.9
6–25 (N = 96) 49: 47 80 72.0 31.3 56.3 83.3
26–45 (N = 53) 26.5: 73.5 90 58.5 15.0 54.7 79.2
46–80 (N = 22) 23: 77 69 54.5 0.0 68.2 86.4
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Age related IgE profiles to peanut allergens
Specific IgE sensitization to the individual peanut aller-
gens differed between the four age groups. Sensitiza-
tion to the major storage proteins was highest in the 
youngest age groups and lowest in the oldest age group. 
The decrease according to age was especially marked 
with respect to Ara h 2 (Fig.  2). The youngest children 
(0–5  years) were most frequently sensitized to the seed 
storage protein Ara h 2 (58.0 %), but were frequently co-
sensitized to Ara h 1 (44 %) and Ara h 3 (27 %) in differ-
ent combinations. The four sera with sIgE to Ara h 6 were 
all from patients in the small children’s group. Sensitiza-
tion to the lipid transfer protein Ara h 9 was seen in all 
age groups (only one positive in the children’s group) but 
most frequently among the young adults (26–45  years) 
(Fig.  2). The birch pollen homologue Ara h 8 increased 
markedly in frequency from 23.3 % in the youngest chil-
dren to 56.3  % at the age of 6  years and was found to 
be 68.2  % in oldest age group. Similarly, sensitization 
to birch pollen showed a marked increase in frequency 
of sensitization from 41.9 % in the youngest children to 
83.3 % at the age of 6 and showed similar high frequen-
cies in the two older age groups (86.4 %) (Fig. 2). A level 
of sIgE to Ara h 2 > 2.0 kU/l, considered to be diagnostic 
for clinical peanut allergy [19], was found in 51.2 % of the 
sera from patients in the youngest age group. Sera with 
levels above this value decreased with age to 31.3 % in the 
second age group, 15 % in the third age group to none in 
the oldest age group (Table 1).
Co-sensitizations, to 1, 2 or 3 other food allergens or to 
more than 3 food allergens were equally common in all 
age groups. The most common sensitizations to allergens 
other than peanut were to other legumes, celery, wheat, 
seeds and tree nuts.
Discussion
The pattern of sensitization to the six individual peanut 
allergens Ara h 1, 2, 3, 6, 8 and 9 was evaluated in patients 
reported to the Norwegian Food Allergy Register. Fre-
quency analysis of the ages of the 214 patients sensitized 
to peanut showed four age groups; 0–5, 6–25, 26–45 and 
46–80  years (Fig.  1). The sensitization pattern showed 
highest frequency of sIgE to the major peanut allergens 
Ara h 2/6, 1, and 3 in the youngest age group (58.5  %) 
and lowest frequency in the oldest age group (4.5 %), as 
opposed to the birch pollen homologue Ara h 8 which 
showed the highest frequency of sensitization in the old-
est age group (68.2 %) and lowest frequency of sensitiza-
tion in the youngest age group (23.3 %) (Fig. 2; Table 1).
Similar changes in gender distribution by age, as pres-
ently observed, from 76:24 % male:female in the young-
est age group to the opposite ratio in the oldest group, 
has been reported for both asthma and allergy and is 
explained by hormonal changes, genetic susceptibil-
ity and differences in environmental exposure. The early 
onset of sensitization to the major peanut allergens and 
the early onset from intake of food to elicitation of symp-
toms in the children’s group, together with high incident 
of more than one organ system affected, indicate that 
the reactions were severe in these patients. Although the 
medical treatment of allergic reactions will vary between 
the individual doctors, all patients were treated with anti-
histamines, epinephrine and steroids or a combination 
of the three, indicating that the reactions were consid-
ered to be severe. Severity, however, based on the reports 
of symptoms, and the medication given is difficult to 
measure since it will depend on at which time course 
of reaction the patients were treated. An early onset of 
effective treatment will always be aimed at to avoid the 
most severe reactions which may explain why loss of con-
sciousness and cardiac arrest was seldom reported.
The results showed the highest frequency of sensitiza-
tion to Ara h 2, less to Ara h 1 and to a much less extent to 
Ara h 3 in the youngest children. Ara h 2 and Ara h 6 have 
been found to account for the majority of the effector 
activity in crude peanut extract [20], with equal diagnostic 
value [21] and hence, to be more potent than Ara h 1 and 
Ara h 3 [22]. However, co-sensitization to all 3 allergens 
has been shown to be correlated to severity of symptoms 
[23]. In the present study, sIgE to Ara h 6 was detected in 
four sera from the youngest children. Sensitization to Ara 
h 6 without concomitant sensitization to Ara h 2 was also 
reported in a Swedish study to be responsible for severe 
reactions [24]. In two of the present cases, sIgE levels to 
Ara h 6 were high (20.0 and 7.9 ISU) and the patients 
were reported to react with acute anaphylactic reaction 
after intake of one peanut. In the other two cases, how-
ever, with low sIgE levels to Ara h 6 (ISU 0.3 and 4.0), 
Ara h 1 Ara h 2 Ara h 3 Ara h 6 Ara h 9 Ara h 8 Birch pollen
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Fig. 2 Sensitization pattern of specific IgE-antibodies to the peanut 
allergens and birch pollen extract in the four age groups showing 
highest frequency of sensitization to Ara h 2 in the youngest age 
groups, and highest frequency of sensitization to Ara h8 from the age 
of 6 years and in the older age groups
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high levels of sIgE to cashew nut was detected. This may 
indicate primary sensitization to cashew nut with cross-
reactivity to Ara h 6 due to sequence identity between 
storage proteins. The early onset of severe peanut allergy 
in children found in the present study is in line with find-
ings in other population studies in children [7, 25, 26]. 
Further, in the studies comparing immunological differ-
ences among patients of different ages and in different 
geographical regions, early onset of sIgE to the three aller-
gens Ara h 1, 2 and 3 were also reported, often presented 
with severe symptoms [13, 14, 16]. One may speculate if 
the high sensitization rate to the major peanut allergens 
in the youngest children is due to dietary changes with 
an increase in the overall use of peanuts in foods and as 
snacks over the last decades and/or as Ballmer-Weber 
et al. [16] speculates, an increase due to an intestinal per-
meability in genetically predisposed children. A recent 
study [27], however, showed that delayed oral exposure to 
peanut was associated with a greater frequency of clini-
cal peanut allergy and hence may be responsible for the 
increased prevalence in this age group.
A study from Italy [28] reported no differences in sen-
sitization among ages up to 16 years for the major pea-
nut allergens, but reported increased levels of sIgE to 
Ara h 8 according to age, as found in the present study. 
The high correlation of sIgE levels to birch pollen extract 
and Ara h 8 may suggest primary pollen sensitization 
with following cross-reaction to Ara h 8, and possibly to 
other labile PR-10 proteins homologous to Bet v 1. The 
increase, however, in sensitization to birch pollen and 
Ara h 8 observed at the early age of 6 years, may, in part, 
be due to a milder climate and thereby longer pollen sea-
son [29]. Even if cross-reactions in general are considered 
to give milder reactions than sensitization to the major, 
stable allergens, the symptoms may have been experi-
enced as severe and treated and reported as such. Thirty-
seven (34 %) of the patients, however, with sIgE to Ara h 
8 were co-sensitized to the three peanut storage proteins 
in different combinations, and may in these cases have 
been responsible for the severe reactions reported. Reac-
tions caused by cross-sensitizations or co-sensitization to 
other food allergens than peanut cannot be ruled out.
All sera with sIgE to the lipid transfer protein Ara h 9, 
also had sIgE to Pru p 3 with similar sIgE levels and half 
of these patients were co-sensitized in different combi-
nations to Ara h 1, 2, 3 and 8. All sera were in addition 
co-sensitized to other foods and often to hazelnut. The 
severe symptoms reported may, therefore, have been 
caused by sensitization to the major peanut allergens or 
by cross-reactions to LTP in hazelnut rather than to Ara 
h 9. The diagnostic value of Ara h 9 is said to be poor [19] 
and the clinical relevance of sensitization to Ara h 9 is 
difficult to interpret.
Various thresholds for sIgE to Ara h 2 have been sug-
gested to predict clinically relevant peanut allergy but 
regional differences in addition to large individual varia-
tions make extrapolations between studies difficult [16]. 
The use of recombinant allergens, therefore, may be use-
ful to distinguish patients with high risk of severe symp-
toms from those with less severe symptoms but cannot 
still replace oral challenges in determining thresholds and 
severity. Although the cases reported in the present study 
were submitted by first-line doctors who considered the 
reactions as being severe, the weaknesses of the study are 
that the results are based on cases with reported symp-
toms and serological analysis not verified by oral chal-
lenges. Hence, the overall information given including the 
severity of symptoms may have been biased by the report-
ing habits of the doctors. Further, the volume of the serum 
sample submitted, were in some cases small which limited 
the number of analysis. Still, the results from the submit-
ted reports and the present analyses of peanut allergens in 
sensitized subjects, contribute to the information on pea-
nut sensitization patterns in different populations.
Conclusion
Component based analysis of peanut in patient sera from 
cases reported to the Norwegian Food Allergy Register 
sensitized to peanut, demonstrate a clear age depend-
ent pattern. The early onset of sensitization to the main 
allergens Ara 1, 2 and 3 found in the children below the 
age of 6 years, showed highest frequency of sIgE to Ara h 
2, indicating the importance of using Ara h 2 in diagnos-
ing small children sensitized to peanut. The early debut 
of pollen sensitization, may be caused by warmer climate 
and longer pollen season and suggest a majority of pri-
mary sensitization to birch pollen from the age of 6 years, 
with following cross-sensitization to the birch pollen 
homologue Ara h 8 in peanut.
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